[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565455":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":26,"studyPopulation":27,"armGroups":28,"interventions":47,"overallOfficials":63,"centralContacts":68,"locations":77,"responsibleParty":128,"collaborators":130,"id":135,"slug":22,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":22,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":142,"minAge":143,"maxAge":22,"enrollmentInfo":144,"targetDuration":147,"studyType":148,"phases":22,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":108,"whyStopped":22,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Kolding Sygehus","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Correlation between kidney biopsy and urinay extracellular vesicles","The primary outcome is to investigate the correlation between histological findings from kidney biopsy and urinary extracelluar vesicles, with the aim of assessing whether there is concordance between the two methods in relation to disease severity and classification.","Urinary extracellular vesicles will be isolated from urine collected at the day of kidney biopsy\u002Fbaseline. Analysis will be performed when all samples are collected. Estimated after 5 years.",{"measure":14,"description":15,"timeFrame":16},"Complement activation in urinary extracellular vesicles","Urinary extracellular vesicles will be isolated. Complement activation will be detected using an in-house ELISA assay","Measured on urinary extracellular vesicles obtained at the day of biopsy\u002Fbaseline. Analysis will be performed when all samples are collected, estimated after 5 years.",[18],{"measure":19,"description":20,"timeFrame":21},"Correlation between urinary extracellular vesicles and extracellular vesicles from plasma","A seconday outcome is to invesigate the correlation between urinary extracellular vesicles and extracellular vesicles from plasma, to see if the same results could be obtained in plasma samples","Blood- og and urine samples will be collected at the day of kidney biopsy\u002Fbaseline. Analysis will be performed when all samples are collecting, estimated after 5 years.",null,{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":24,"timePerspective":25,"maskingInfo":22},"COHORT","PROSPECTIVE","Introduction: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified based on its histopathological features. The classification helps in determining the severity and appropriate treatment strategies for the condition and to rule out other conditions that may mimic the clinical picture of LN. The classification system most commonly used is the International Society of Nephrology\u002FRenal Pathology Society (ISN\u002FRPS) classification, which divides lupus nephritis into six classes: I) Minimal Change, II) Mesangial Proliferative LN, III) Focal Proliferative LN, IV) Diffus proliferative LN, V) Membranous LN, VI) Advanced Sclerosing LN. The classification requires invasive kidney biopsies, which are hardly accessible and associated with potential complications and patient discomfort. Furthermore the kidney biopsy only represent a small part of the kidney. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers for kidney diseases, including LN. uEVS are small nano-sized extracellular vesicles of endosomal origin, which are secreted into the urine through fusion of multivesicular bodies with the plasma membrane. Thus, they could represent a promising liquid biopsy that reflects the pattern and\u002For severity of renal injury.\n\nHypothesis: The primary objective of this prospective study is to investigate the utility of urinary exosomes as non-invasive biomarkers for monitoring the activity and progression of lupus nephritis.\n\nMethods: SLE patients, fulfilling the 2019 EULAR\u002FACR classification criteria, referred to kidney biopsy, will be recruited from Department of Rheumatology and Department of Nephrology at Odense University Hospital. Detailed demographic and clinical data including age, sex, ethnicity, medicine, duration of SLE activity, SLE damage and laboratory results will be collected from each patient. Activity of SLE at the time of biopsy will be evaluated using SLE disease activity index 2000 (SLEDAI-2K). SLE damage will be evaluated in accordance with the SLICC damage index. Spot-urine samples will be collected, added protease-inhibitors and frozen at -80 degree. UEVs will be isolated using polyethylene glycol (PEG) precipitation, the concentration of uEV will be determined and protein accessed using western blotting and\u002For PCR. Glomerular specific uEVs will be isolated and previous developed tests will be applied to detect the membrane attack complex (MAC)\u002FC5b-9 complex. uEVs from plasma\u002Fserum will be isolated to test for correlation with uEVs. Kidney biopsies will be histological analyzed at Department of Pathology by experienced nephropathologists according to existing clinical guidelines. Differences in uEV cargo between SLE patients with and without lupus nephritis will be analyzed using appropriate statistical tests. Correlations between uEV biomarkers, histological differences on the kidney biopsy and disease activity will be evaluated using Pearson's correlation analysis.\n\nPerspective: This prospective study aims to establish urinary extracellular vesicles as potential non-invasive biomarkers for monitoring lupus nephritis in SLE patients. The findings from this research may lead to the development of more efficient and patient-friendly approaches for LN management, enabling timely interventions and improved renal outcomes in SLE patients.","Patients known with SLE with and without kidney involvement, a biopsy control and a group of healthy controls.",[29,36,40,43],{"label":30,"type":22,"description":31,"interventionNames":32},"Systemic lupus erythomatosus with lupus nephritis","SLE patients with kidney involvement",[33,34,35],"Diagnostic Test: Kidney biopsy","Diagnostic Test: Urinary extracellular vesicle testing","Diagnostic Test: Autoimmunity in plasma",{"label":37,"type":22,"description":38,"interventionNames":39},"Systemic lupus erythomatosus without lupus nephritis","SLE patients, fulfilling the 2019 EULAR\u002FACR classification criteria with no sign of kidney disease",[34,35],{"label":41,"type":22,"description":41,"interventionNames":42},"Healthy controls",[34],{"label":44,"type":22,"description":45,"interventionNames":46},"Biopsy controls","A biopsy control group with no predictive complement activation referred to biopsy",[33,34],[48,55,59],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"DIAGNOSTIC_TEST","Kidney biopsy","Patient refered to kidney biopsy independent of the presented study",[44,30],[54],"No expected complement activation",{"type":49,"name":56,"description":57,"armGroupLabels":58,"otherNames":22},"Urinary extracellular vesicle testing","Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease",[44,41,30,37],{"type":49,"name":60,"description":61,"armGroupLabels":62,"otherNames":22},"Autoimmunity in plasma","Expected autoimmunity in plasma isolated from blood samples",[30,37],[64],{"name":65,"affiliation":66,"role":67},"Anne F Christensen, Chief of Medicine, MD, phd","Sygehus Lillebaelt, Kolding Hospitl","STUDY_CHAIR",[69,74],{"name":70,"role":71,"phone":72,"phoneExt":22,"email":73},"Rikke Z Langkilde, MD, phd","CONTACT","4530281347","rikke.zachar.langkilde@rsyd.dk",{"name":75,"role":71,"phone":22,"phoneExt":22,"email":76},"Anne D Thuesen, MD, phd, clinical lector","anne.daugaard.thuesen2@rsyd.dk",[78,94,106,117],{"facility":79,"status":80,"city":81,"state":22,"zip":22,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Kolding Hospital","NOT_YET_RECRUITING","Kolding","Denmark","DK",{"type":85,"coordinates":86},"Point",[87,88],9.47216,55.4904,{"lat":88,"lon":87},[91],{"name":92,"role":71,"phone":93,"phoneExt":22,"email":76},"Anne D Thuesen, Head of research, MD, phd","004576360555",{"facility":95,"status":80,"city":96,"state":22,"zip":97,"country":82,"countryCode":83,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Department of Nephrology","Odense","5000",{"type":85,"coordinates":99},[100,101],10.38831,55.39594,{"lat":101,"lon":100},[104],{"name":105,"role":71,"phone":22,"phoneExt":22,"email":22},"michael Aarup, MD, consultant",{"facility":107,"status":108,"city":96,"state":22,"zip":97,"country":82,"countryCode":83,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Department of Rheumatology","RECRUITING",{"type":85,"coordinates":110},[100,101],{"lat":101,"lon":100},[113],{"name":114,"role":71,"phone":115,"phoneExt":22,"email":116},"Henrik Z Langkilde, MD","21279653","henrik.zachar.langkilde@rsyd.dk",{"facility":118,"status":80,"city":96,"state":22,"zip":119,"country":82,"countryCode":83,"cosmosGeoPoint":120,"geoPoint":122,"contacts":123},"Univesity of Southern Denmark","5230",{"type":85,"coordinates":121},[100,101],{"lat":101,"lon":100},[124],{"name":125,"role":71,"phone":126,"phoneExt":22,"email":127},"Per Svenningsen, professor","004565501000","psvenningsen@health.sdu.dk",{"type":129,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[131,133],{"name":132,"class":6},"University of Southern Denmark",{"name":134,"class":6},"Odense University Hospital","100565455",false,"NCT06642402","Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles","Monitoring and Detecting Lupus Nephritis Through Urinary Extracellular Vesicles in Urine","SLE patients with kidney involvement\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nSLE patients with no sign of kidney disease\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Normal plasma creatinine\n* Urine albumine\u002Fcreatinine \\\u003C 100 mg\u002Fg\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nHealthy controls:\n\nInclusion criteria:\n\n* \\> 18 years old\n* No known kidney disease\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Urine albumin-creatinine ratio \\> 100 mg\u002Fg or proteinuria \\> 100 mg\u002Fday\n* Postive autoantibodies\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nBiopsy control:\n\nInclusion criteria:\n\n* \\> 18 years old\n* Negative autoantibiodies and immunoglobulines\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome",true,"ALL","18 Years",{"count":145,"type":146},40,"ESTIMATED","1 Year","OBSERVATIONAL","Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.",[151],"Systemic Lupus Erythematosus Nephritis",[153,154,155,156],"Systemic Lupus Erythoematosus nephritis","Lupus nephritis","complement activation","kidney biopsy","2025-09-02",{"date":159,"type":160},"2025-09-09","ACTUAL",{"date":162,"type":160},"2024-11-15",{"date":164,"type":146},"2030-05-01",{"name":5,"class":6},4]